STAAB THOMAS R II 4

What Happened
Thomas R. Staab II, Chief Financial Officer of Tenax Therapeutics (TENX), was granted a 10,000-share restricted stock award and a derivative award covering 450,000 shares (options/other equity derivative) on May 11, 2026. Both awards show a $0 acquisition price in the filing (i.e., no cash paid). These are grants/awards — not open-market purchases or sales.

Key Details

• Transaction date: May 11, 2026; Form 4 filed May 13, 2026 (timely — reported two days after the transaction).
• Awards: 10,000 restricted shares @ $0; 450,000 derivative shares (options/award) @ $0.
• Amount owned after transaction: Not specified in the provided filing excerpt.
• Footnote F1 (10,000 shares): 25% vests 10 days after grant; remainder vests in three equal installments at 4-, 8-, and 12-month anniversaries, subject to continued employment.
• Footnote F2 (450,000 derivative): Options vest 25% on May 11, 2027, then the rest in substantially equal monthly installments over a 36-month period, subject to continued employment.
• Transaction code: A = Award/Grant (no immediate sale or exercise reported).

Context
These entries are equity awards from the company, not open-market buys or sales; awards typically compensate executives and vest over time, so they do not necessarily reflect immediate bullish trading. The derivative grant (options) will vest over multiple years and is contingent on continued employment; there is no indication shares were sold or exercised at filing.